<DOC>
	<DOC>NCT01667718</DOC>
	<brief_summary>To examine and compare the efficacy of 2 week Levofloxacin-containing therapies with and without Bismuth for H.pylori treatment.</brief_summary>
	<brief_title>Bismuth Improves the Efficacy of Levofloxacin-containing Triple Therapy for Helicobacter Pylori Treatment</brief_title>
	<detailed_description>The success rate of the standard triple therapy for H. pylori infection is decreasing recently.Fluoroquinolone has been proposed to replace clarithromycin as an alternative in the treatment. However prevalence of H.pylori resistance to Levofloxacin has increased rapidly in our area. The purpose of this study is to observe the efficacy of 14 day Levofloxacin triple therapy-based, bismuth-containing quadruple therapy for H.pylori treatment.</detailed_description>
	<mesh_term>Dyspepsia</mesh_term>
	<mesh_term>Peptic Ulcer</mesh_term>
	<mesh_term>Lansoprazole</mesh_term>
	<mesh_term>Dexlansoprazole</mesh_term>
	<mesh_term>Proton Pump Inhibitors</mesh_term>
	<mesh_term>Levofloxacin</mesh_term>
	<mesh_term>Ofloxacin</mesh_term>
	<mesh_term>Bismuth</mesh_term>
	<mesh_term>Amoxicillin</mesh_term>
	<mesh_term>Potassium Citrate</mesh_term>
	<criteria>patients who presented with upper gastrointestinal symptoms and endoscopically proven H.pyloripositive functional dyspepsia and scarred peptic ulcer patients with peptic ulcer, previous H.pylori eradication therapy, previous gastric surgery, pregnancy, lactation, major systemic diseases, receipt of antisecretory therapy, antibiotics or bismuth in the preceding 4 weeks, or allergy to any one of the medications</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>eradication</keyword>
	<keyword>helicobacter pylori</keyword>
	<keyword>bismuth</keyword>
</DOC>